Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for camrelizumab-induced RCCEP (phase II, single-arm)
ChiCTR2400087118Phase 2Not yet recruiting
- Sponsor
- PLA General Hospital Seventh Medical Center
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in lobular capillary hemangioma (PG) and Non-hematologic malignancy, sponsored by PLA General Hospital Seventh Medical Center. Primary endpoint: 3-week RCCEP remission rate. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
thalidomide
03
Conditions
lobular capillary hemangioma (PG)Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2400087118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087118.